![]()
|
|
||||||||
J Biol Chem, Vol. 273, Issue 36, 22913-22920, September 4, 1998
- and
-Chains of Hepatocyte
Growth Factor on c-Met Receptor Confers Ligand-induced Receptor
Tyrosine Phosphorylation and Multiple Biological Responses*
From the Division of Biochemistry, Biomedical Research Center, Osaka University Medical School, Suita, Osaka 565-0871, Japan
| |
ABSTRACT |
|---|
|
|
|---|
Hepatocyte growth factor (HGF) is a heterodimeric
molecule composed of the
-chain containing the N-terminal hairpin
domain, four kringle domains, and the serine protease-like
-chain.
We prepared HGF/NK4 and HGF/
from the entire HGF after single-cut digestion with elastase. HGF/NK4 contains the N-terminal hairpin and
four kringle domains, while HGF/
is composed of the C-terminal 16 amino acids of the
-chain and the entire
-chain, linked by a
disulfide bridge. HGF/NK4 competitively inhibited the binding of
125I-HGF to the receptor, and affinity cross-linking
analysis indicated that HGF/NK4 alone can bind to the c-Met receptor.
In contrast, HGF/
alone did not competitively inhibit the binding of
125I-HGF to the receptor and did not bind to the c-Met/HGF
receptor. Scatchard analysis and affinity cross-linking experiments
indicated that HGF/
specifically binds to c-Met in the presence of
HGF/NK4 but not HGF/NK2. Neither HGF/NK4 nor HGF/
alone induced
mitogenic, motogenic (cell scattering), and morphogenic (induction of
branching tubulogenesis) responses; however, HGF/
did induce these
biological responses in the presence of HGF/NK4. Consistent with these
results, although neither HGF/NK4 alone nor HGF/
alone induced
tyrosine phosphorylation of the c-Met/HGF receptor, HGF/
induced
tyrosine phosphorylation of the receptor when c-Met/HGF receptor was
occupied by HGF/NK4. These results indicate that HGF/
binds to the
c-Met/HGF receptor that is occupied by HGF/NK4 and induces receptor
tyrosine phosphorylation and the subsequent biological activities of
HGF. We propose that there exists a unique cooperative interaction between
- and
-chains, this interaction leading to
-chain-dependent receptor tyrosine phosphorylation and
subsequent biological responses.
| |
INTRODUCTION |
|---|
|
|
|---|
Coupling between hepatocyte growth factor (HGF)1 and its receptor, c-met protooncogene product of heterodimeric tyrosine kinase integrates mitogenic, motogenic, and morphogenic activities in a wide variety of cells (1-3). Most epithelial cells and several types of mesenchymal cells are target cells of HGF (1-3). Physiologically, HGF is a potent "trophic" factor for regeneration of organs (3), and it possesses potent angiogenic activity (4, 5). In addition to roles in epithelial and endothelial tissues, HGF is an important regulator in the maintenance of stromal tissues and cells, including bone formation (6), chondrogenesis (7), and hematopoiesis (8, 9). The particular importance of HGF and c-Met/HGF receptor in developmental processes was demonstrated by targeted mutation of HGF or c-Met/HGF receptor gene (10-13). HGF is essential for the development of the liver and placenta, and it supports migration of myogenic precursor cells. In vitro analysis also showed that HGF supports morphogenic events during development of the kidney, mammary gland, lung, and tooth (1-3, 14-16). Together with a preferential expression of HGF in mesenchymal (or stromal) tissue (17, 18), HGF is considered to be a mesenchymal-derived mediator in epithelial-mesenchymal (or -stromal) interactions during organogenesis and organ regeneration.
Biologically active HGF is a disulfide-linked heterodimer composed of a
69-kDa
-chain and a 34-kDa
-chain (19-21). The
-chain contains the N-terminal hairpin domain and subsequently four homologous kringle domains, while the
-chain contains a serine protease-like domain (22). To address the specific function of each subunit in the
HGF molecule, variously mutated variant HGFs were tested for biological
activities and receptor binding. A small molecule consisting of the
N-terminal hairpin domain, the first kringle domain (K1), and the
second kringle domain (K2), designated HGF/NK2 exists as a naturally
biosynthesized variant form, and HGF/NK2 can bind the c-Met/HGF
receptor (23-26). Importantly, HGF/NK2 shows motogenic activity,
i.e. enhancement of cell motility, but lacks mitogenic
activity (23, 25-27). Thus, HGF/NK2, capable of receptor binding, is
an antagonist for the mitogenic activity of HGF (23), yet retains
selective agonistic activity in terms of cell motility (25, 27).
Subsequently, Lokker and Godowski (28) showed that HGF/NK1, composed of
the N-terminal hairpin domain and K1, can bind to the c-Met/HGF
receptor, while Cioce et al. (29) reported that HGF/NK1 is a
naturally occurring variant with partial agonistic or antagonistic
activity in a different assay system. On the other hand, the
-chain
alone cannot bind to the c-Met/HGF receptor and has none of the
biological activities of HGF (25, 26, 30, 31). Nevertheless, deletion
of the
-chain in HGF results in loss of biological activities of
HGF, even though the
-chain alone can bind to the c-Met/HGF receptor
(25, 30, 31).
Previous studies clarified the specific function of the N-terminal half
of the
-chain (HGF/NK2), as a receptor-binding motif, as well as a
partial agonist in terms of motogenic activity. Thus, biological
function of the
-chain remained to be specified. We recently
obtained the antagonist for HGF, termed "HGF/NK4" (32). HGF/NK4
contains the N-terminal hairpin structure and four kringle domains. We
have now obtained evidence which supports the proposal that the
-chain can bind to the c-Met/HGF receptor which is specifically occupied with HGF/NK4, and that this cooperative binding induces receptor tyrosine phosphorylation of c-Met, leading to mitogenic, motogenic, and morphogenic responses. The
-chain of HGF can bind to
the c-Met/HGF receptor, but the optimum activation of c-Met/HGF receptor for the transduction of multiple biological activities of HGF
depends on the
-chain.
| |
EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Materials--
Human recombinant HGF was purified from the
conditioned medium of Chinese hamster ovary cells transfected with
human HGF cDNA (22, 33). HGF used in the present study was of the
5-amino acid-deleted type (33). The purity of HGF exceed 98%, as
determined by SDS-PAGE and protein staining. Anti-phosphotyrosine
monoclonal antibody (PY-20) was obtained from Chemicon International
Inc. (Temecula, CA) and anti-c-Met polyclonal antibody (C-12) from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Pyroglutamate aminopeptidase was obtained from TAKARA Co. Ltd. (Otsu, Japan). Monoclonal antibody against the
-chain of HGF was prepared as described elsewhere (34).
Preparation of HGF/NK4, HGF/
, and HGF/NK2--
Human
recombinant HGF was digested with pancreatic elastase (Sigma), and the
digested material was applied onto µBondapak C4 reverse-phase HPLC
column and adsorbed materials were eluted with a gradient of
acetonitrile containing 0.05% (v/v) trifluoroacetic acid (32). HGF/
was further purified using a Hi-Trap heparin column (Amersham Pharmacia
Biotech, Uppsala). The preparation of HGF/
was rechromatographed on
C4 reverse-phase HPLC, as described above. The final preparation of
HGF/
used in this study contained 0.003% (in molar ratio) of intact
HGF, as detected by enzyme-linked immunosorbent assay (32). Biochemical
analysis indicated that HGF/NK4 is composed of the N-terminal hairpin
and subsequent four kringle domains, which corresponds to the
-chain
deleted with C-terminal 16 amino acids, while HGF/
is composed of
the C-terminal 16 amino acids of the
-chain and the entire
-chain, linked by a disulfide bridge between Cys487 and
Cys604 (Fig. 1A).
Cell Culture and Measurement of DNA Synthesis--
MDCK (clone
3B) renal epithelial cells, a kind gift from Dr. R. Montesano
(University of Geneva) were cultured in DMEM containing 10% fetal calf
serum. HuCC-T1 human cholangiocarcinoma and A549 human lung
adenocarcinoma cells were obtained from the Japanese Cancer Research
Resources Bank and cultured in DMEM containing 10% fetal calf serum.
For migration assay, MDCK cells were seeded on a 48-well plate at a
density of 2.5 × 103 cells/well in DMEM containing
10% fetal calf serum, with or without test samples. The cells were
cultured for 20 h, then photographed. For three-dimensional
culture in collagen gels, MDCK cells were harvested using trypsin-EDTA
solution, suspended in ice-cold 0.2% collagen solution (Nitta Gelatin,
Tokyo) at a density of 104 cells/ml, and 500-µl aliquots
were added to wells of a 16-mm width (Nunc, Roskilde, Denmark). After
the collagen solution gelled, 500 µl of culture medium containing
HGF, HGF/NK4, and/or HGF/
were added. Culture medium was changed
every 3 days.
, or their combinations was
measured using adult rat hepatocytes in primary culture, as described
elsewhere (30). HGF, HGF/NK4, HGF/
, HGF/NK2, or their combinations
were added to cultures of hepatocytes, the culture was run for 20 h, and then pulse-labeled with 0.3 µCi/ml 125I-deoxyuridine for 6 h. The cells were washed twice
with phosphate-buffered saline and once with trichloroacetic acid, then
solubilized with 1 M NaOH. Radioactivity of
125I-deoxyuridine incorporated into nuclei was measured
using a
-counter.
Radiolabeled Ligand Binding Assay to the c-Met/HGF
Receptor--
HGF, HGF/NK4, and HGF/
were respectively
radioiodinated by the chloramine-T method, as described elsewhere (32).
The competitive binding assay was performed by incubating 60 pM 125I-HGF and various concentrations of
unlabeled HGF, HGF/NK4, or HGF/
, simultaneously with 50 µg of
plasma membranes from rat livers at 12 °C for 1 h, in 0.1 ml of
binding buffer (Hanks' solution containing 20 mM HEPES and
2 mg/ml bovine serum albumin, pH 7.0). Membranes were centrifuged at
12,000 × g for 10 min at 4 °C, resuspended with 10 µl of binding buffer and transferred to fresh tubes.
125I-HGF specifically bound to membranes was measured using
a
-counter.
, with or without 100 times excess molar unlabeled HGF or HGF/
, was added, and the
preparation was incubated at 12 °C for 1 h. Cultures were
washed three times with ice-cold binding buffer, and radiolabeled
ligand bound to cells was measured. All binding experiments were done
in quadruplicate.
Detection of Receptor Tyrosine Phosphorylation--
Subconfluent
A549 cells were cultured in serum-free DMEM supplemented with 0.2%
(w/v) bovine serum albumin for 20 h. The cells were treated with
HGF, HGF/NK4, and/or HGF/
, washed with phosphate-buffered saline
containing 1 mM Na3VO4, and the
cell lysate was centrifuged at 12,000 × g for 10 min,
as described previously (32). The resultant supernatant was preadsorbed
with protein A-Sepharose (Amersham Pharmacia Biotech) and centrifuged
at 12,000 × g for 10 min. The supernatant was treated
with anti-human c-Met antibody and protein A-Sepharose.
Immunoprecipitated materials were washed with lysis buffer and
solubilized with sample buffer for SDS-PAGE. The immunoprecipitates
were separated by SDS-PAGE, electroblotted onto a polyvinylidene
difluoride membrane (Bio-Rad, Hercules, CA), and probed with
anti-phosphotyrosine monoclonal antibody or anti-c-Met antibody.
Proteins reacting with these antibodies were detected using ECL
enhanced chemiluminescence (Amersham, Little Chalfont, UK).
Affinity Cross-linking-- HuCC-T1 cells cultured in a 90 mm dish were washed twice with ice-cold binding buffer consisting of Hanks' balanced salt solution containing 20 mM HEPES-NaOH (pH 7.0) and 0.2% (w/v) bovine serum albumin and incubated in the binding buffer for 30 min at 10 °C. The binding buffer was changed to fresh binding buffer, and the radiolabeled ligand was added. After 1 h of incubation at 10 °C, bis(sulfosuccinimidyl) suberate (Pierce) was added at the final concentration of 0.5 µM, and the cells were incubated 1 h at 4 °C. After cells had been washed twice with phosphate-buffered saline, the cells were lyzed and scraped into buffer composed of 20 mM Tris-HCl (pH 7.4), 10 mM EDTA, 150 mM NaCl, 5 µg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, 0.5% Triton X-100. The cell suspension in a siliconized tube was centrifuged at 15,000 rpm for 10 min, and the supernatant was preadsorbed with 25 µl of protein A-Sepharose (Amersham Pharmacia Biotech) for 1 h at 4 °C. After centrifugation at 5,000 rpm for 5 min, the supernatant was treated with rabbit anti-c-Met antibody for 2 h at 4 °C, then 7.5 µl of protein A-Sepharose was added. The preparation was centrifuged, and the precipitated material was washed four times with lysis buffer and solubilized in the sample buffer for SDS-PAGE. The solubilized proteins were subjected to SDS-PAGE, using 2-15% gradient gel, and the gel was subjected to autoradiography.
| |
RESULTS |
|---|
|
|
|---|
Receptor Binding Ability of HGF/NK4 and HGF/
--
To determine
whether HGF/NK4 and HGF/
can bind to the cell surface receptor,
competitive binding analysis was carried out using 125I-HGF
(Fig. 1B). Liver plasma
membranes were incubated in the presence of 125I-HGF alone,
or 125I-HGF plus various concentrations of unlabeled HGF,
HGF/NK4, or HGF/
. Addition of unlabeled HGF inhibited the specific
binding of 125I-HGF to the plasma membranes, and 50%
inhibition by unlabeled HGF was seen with 60 pM HGF; the
dose being approximately equimolar to that of 125I-HGF.
|
did not inhibit the binding of
125I-HGF, at least up to 30 nM, the maximal
concentration tested here. Therefore, HGF/NK4 seems to bind to the
c-Met/HGF receptor with a 10-fold lower affinity than that of the
native HGF; however, HGF/
does not bind to the receptor.
Mitogenic Activity of HGF/NK4 and HGF/
--
We next examined
the mitogenic activity of HGF/NK4 and HGF/
, using adult rat
hepatocytes in primary culture (Fig.
2A). Addition of 100 pM HGF potently stimulated DNA synthesis to over 10-fold higher levels. In contrast, addition of HGF/
alone up to 30 nM had no apparent effect on DNA synthesis. This result is
consistent with the finding that HGF/
alone cannot bind to the
c-Met/HGF receptor. On the other hand, 1.5 nM HGF/NK4 alone
had no evident effect on DNA synthesis, even though HGF/NK4 at this
concentration seems to occupy most of the c-Met/HGF receptor. However,
it is noteworthy that the addition of HGF/
in the presence of 1.5 nM HGF/NK4 dose-dependently induced mitogenic
responses in hepatocytes, and the maximal stimulatory effect was seen
at 30 nM HGF/
and was 50-60% of that of HGF.
|
would elicit mitogenic
activity, as seen in the combination of HGF/NK4 and HGF/
(Fig.
2B). Although HGF/NK4 plus HGF/
, as well as native HGF,
stimulated DNA synthesis in hepatocytes, HGF/NK2 alone or 30 nM HGF/
plus HGF/NK2 did not stimulate DNA
synthesis.
Motogenic and Morphogenic Activities of HGF/NK4 and
HGF/
--
When HGF was added to the monolayer culture of MDCK
cells, HGF enhanced their motility and induced scattering of the cells (Fig. 3). Neither HGF/NK4 (1.5 nM) alone nor HGF/
(30 nM) alone induced
scattering of the MDCK cells. However, when HGF/
was added to the
culture in the presence of HGF/NK4, HGF/
dose-dependently induced scattering of the cells. The cell
scattering seen with 1.5 nM HGF/NK4 plus 30 nM
HGF/
was comparable to that seen with 100 pM HGF.
Consistent with previous reports (23, 25-27), the addition of HGF/NK2
alone (3.3 nM) induced scattering of MDCK cells (not
shown). On the other hand, Hartmann et al. (25) previously showed that the
-chain of HGF has weak motogenic activity. A discrepancy regarding the biological activity between HGF/NK4 and the
-chain may be attributable to the structural difference between
HGF/NK4 and the
-chain; HGF/NK4 lacks C-terminal 16 amino acids of
the
-chain (Fig. 1A). Importantly, the C-terminal
16-amino acid fragment contains a cysteine residue involved in a
disulfide bond between the
- and
-chain of HGF. When the entire
-chain alone was expressed in mammalian cells, the
-chain formed,
at least, a homodimer, presumably through a disulfide bond between C-terminal-free cysteines. Moreover, the recombinant
-chain
preparation showed weak motogenic
activity.2 Covalently
dimerized
-chain may induce receptor dimerization and thus allow low
level signaling, leading to cell scattering.
|
have morphogenic activity
(Fig. 4). When MDCK cells were grown in a
collagen gel matrix, they form spherical cysts, but when grown in the
presence of HGF, branching tubulogenesis occurred. Neither HGF/NK4
alone, nor HGF/
induced branching tubular structures in the MDCK
cells; however, the addition of HGF/
in the presence of 1.5 nM HGF/NK4 did induce branching tubulogenesis, as seen with
the native HGF. These results indicate that the combination of HGF/NK4
and HGF/
elicits mitogenic, motogenic, and morphogenic activities,
all typical for multiple biological activities of HGF, although neither
HGF/NK4 alone nor HGF/
alone has biological activities.
|
Induction of c-Met Tyrosine Phosphorylation--
Multiple
biological activities of HGF depend on tyrosine phosphorylation of
c-Met/HGF receptor upon HGF binding. We next analyzed tyrosine
phosphorylation of c-Met/HGF receptor in A549 cells (Fig. 5). Tyrosine phosphorylation of c-Met/HGF
receptor was not seen in nonstimulated cells, but addition of HGF
induced tyrosine phosphorylation of the c-Met/HGF receptor. Neither 1.5 nM HGF/NK4 alone nor 30 nM HGF/
alone
induced tyrosine phosphorylation; however, a combination of HGF/NK4
plus HGF/
dose-dependently induced tyrosine
phosphorylation of the receptor. The tyrosine phosphorylation seen with
1.5 nM HGF/NK4 plus 30 nM HGF/
was slightly
lower than that seen with 100 pM HGF. Taken together,
biological activities of HGF/NK4, HGF/
, and their combination seem
to depend on their potential to induce tyrosine phosphorylation of the
c-Met/HGF receptor.
|
Specific Binding of HGF/
to the Receptor--
Based on above
results, we considered that although HGF/
alone does not bind to the
c-Met/HGF receptor, HGF/
might specifically bind to the receptor in
the presence of HGF/NK4. To test this hypothesis, we analyzed
concentration-dependent binding of radiolabeled HGF and
HGF/
to HuCC-T1 cells (Fig. 6).
Scatchard analysis of concentration-dependent binding of
125I-HGF up to 60 pM resulted in a rectilinear
plot (Fig. 6A, inset). The Kd
value and the number of HGF receptors were calculated to be 36 pM and 2728 sites/cell, respectively. Our previous study demonstrated that 125I-HGF and 125I-HGF/NK4,
respectively, bind to the receptor on rat liver plasma membranes with a
Kd values of 64.5 pM and 486 pM (32), indicating that HGF/NK4 binds to the receptor with
8-fold lower affinity than that of HGF. The value seems to be fairly
consistent with the result of the competitive binding (Fig. 1). On the
other hand, Scatchard analysis on 125I-HGF/
binding
indicated that the Kd value and the number of
binding sites were 14455 pM and 18042 sites/cell,
respectively (Fig. 6B). The abundant binding sites and the
very low affinity suggest that 125I-HGF/
alone seems to
bind nonspecifically to sites clearly distinct from the c-Met/HGF
receptor. However, in the presence of 1.5 nM HGF/NK4,
125I-HGF/
specifically bound to the cells with a higher
affinity than that without HGF/NK4; the Kd value and
the number of binding sites were 2449 pM and 3394 sites/cell, respectively (Fig. 6C). Although the affinity of
HGF/
to the binding sites in the presence of HGF/NK4 was still
68-fold lower than that of HGF, the Kd value of 2449 pM seems to coincide with a biologically effective
concentration for its half-maximal activity (approximately 3 nM) in the presence of HGF/NK4 and the number of binding
sites is fairly close to that for HGF. Together with previous results
that HGF/
induces tyrosine phosphorylation of c-Met/HGF receptor and
subsequent biological responses which specifically occur in the
presence of HGF/NK4, these present results strongly suggest that
HGF/
specifically binds to the c-Met/HGF receptor in the presence of
HGF/NK4.
|
. These results indicate that
the cross-linked products were specifically formed between c-Met/HGF
receptor and 125I-HGF.
|
. Thus, HGF/NK4 alone
can specifically bind to the c-Met/HGF receptor. In contrast, when
125I-HGF/
was added alone, it was not cross-linked with
the c-Met/HGF receptor, indicating that HGF/
alone does not bind to
c-Met/HGF receptor. However, when 125I-HGF/
was added in
the presence of 0.5 nM HGF/NK4, 125I-HGF/
was specifically immunoprecipitated by anti-c-Met antibody, as a
complex with a molecular mass of over 300-500 kDa. The formation of
cross-linked complexes was competitively inhibited by the addition of
an excess amount of unlabeled HGF, as well as HGF/
, indicating that
HGF/
binds to the c-Met/HGF receptor in the presence of HGF/NK4, but
it is competitively inhibited HGF. On the other hand, 125I-HGF/
scarcely cross-linked with the c-Met/HGF
receptor in the presence of HGF/NK2. Therefore, HGF/
forms a complex
with c-Met/HGF receptor in the presence of HGF/NK4, but not
HGF/NK2.
HGF/
Binds and Activates c-Met/HGF Receptor Occupied by
HGF/NK4--
Based on these results, we hypothesized that HGF/NK4
binds and occupies the c-Met/HGF receptor, and subsequently, HGF/
binds to the c-Met/HGF receptor that is occupied with HGF/NK4. To
examine this hypothesis, we analyzed tyrosine phosphorylation of
c-Met/HGF receptor, under the following conditions: 1) A549 cells were
first incubated with 1.5 nM HGF/NK4 at 4 °C for 1 h
and washed three times with culture medium to remove unbound free
HGF/NK4, and then HGF/
was added and the cells were incubated at
37 °C for 20 min; and 2) inversely, the cells were first incubated
with 30 nM HGF/
, washed three times, and then HGF/NK4
was added (Fig. 8).
|
and subsequently with
HGF/NK4, the c-Met/HGF receptor was not tyrosine-phosphorylated (Fig.
8). Likewise, neither pretreatment nor treatment with HGF/NK4 alone
induced tyrosine phosphorylation of the receptor. In contrast, when the
cells were pretreated with HGF/NK4 and subsequently treated with
HGF/
, this sequential treatment induced tyrosine phosphorylation of
the c-Met/HGF receptor (Fig. 8). The addition of HGF in pretreatment or
subsequent treatment induced tyrosine phosphorylation of the receptor.
Taken together, we conclude that HGF/
binds and activates the
c-Met/HGF receptor occupied by HGF/NK4, rather than that HGF/
complexes with HGF/NK4 and subsequently binds and activates the c-Met/HGF receptor.
| |
DISCUSSION |
|---|
|
|
|---|
The unique structural characteristics of HGF as a multipotent
growth factor suggested to us that a specific domain is likely responsible for binding to the c-Met/HGF receptor and/or selective biological activity, i.e. mitogenic, motogenic, or
morphogenic activity of HGF. On the other hand, biological activities
of HGF are mediated through the c-Met/HGF receptor, which integrates complex intracellular signal transduction pathways. The ligand binding
to the c-Met/HGF receptor evokes phosphorylation of tyrosine residues
located in the kinase domain, the event up-regulates tyrosine kinase
activity, and tyrosine phosphorylation in C-terminal tyrosine residues,
so-called multiple docking sites, gathers intracellular signaling
molecules (35-37). How each domain or subunit in the HGF molecule is
involved in activation of the c-Met/HGF receptor upon HGF binding is
virtually unknown; however, a specific domain or subunit is likely to
regulate a distinct event, such as receptor binding, receptor
oligomerization, and tyrosine phosphorylation. We obtained evidence
that supports a cooperative mechanism of
- and
-chains of HGF for
receptor binding and the subsequent activation, as follows: 1) HGF/NK4
alone binds to the c-Met/HGF receptor, but does not induce
tyrosine-phosphorylation of the receptor or elicit biological
activities; 2) HGF/
alone does not bind to the receptor but does
bind to the receptor when the receptor is occupied by HGF/NK4, induces
tyrosine phosphorylation of the receptor, and exerts mitogenic,
motogenic and morphogenic activities; 3) K3 and/or K4 in HGF/NK4 are
required for the binding of HGF/
to the complex of HGF/NK4 and
c-Met/HGF receptor.
Previous studies indicate that HGF/NK2 binds to the c-Met/HGF receptor,
weakly induces tyrosine phosphorylation, and exerts motogenic activity
(23, 25-27, 38). HGF/NK2 has no apparent mitogenic activity in several
types of cells, including hepatocytes and endothelial cells (23, 25,
26, 38) (this study), while it has an apparent mitogenic activity in
some types of cells (39). Silvagno et al. (38) reported that
HGF/NK3 also has no mitogenic activity but has motogenic activity in
endothelial cells. In contrast, HGF/NK4 does not induce tyrosine
phosphorylation and has no apparent biological activities, even though
it does bind to the receptor. We consider that K4 in HGF/NK4 does not
block the specific binding between HGF/NK2 or HGF/NK3 and the c-Met/HGF
receptor, but may suppress the motogenic activity of HGF/NK2 or HGF/NK3
by suppressing weak tyrosine phosphorylation of the receptor. One
possible explanation for the discrepancy in biological activity of
HGF/NK2 or HGF/NK3 and HGF/NK4 is that HGF/NK2 or HGF/NK3 may allow for
partial or residual activation of the c-Met/HGF receptor and thus
partial or low level signaling, leading to cell scattering, but it may not allow for efficient or optimal signaling, leading to cell proliferation and tubule formation. In contrast, the existence of K4 in
HGF/NK4 may induce a conformational change in the c-Met/HGF receptor or
inhibit receptor dimerization, such that tyrosine autophosphorylation
would be mostly impaired. Our results also demonstrated the importance
of K3 and/or K4 in the cooperative interaction among HGF/NK4, HGF/
,
and the c-Met/HGF receptor, which occurs on the cell surface c-Met/HGF
receptor. HGF/
did not induce the mitogenic response nor did it form
a cross-linked complex with the c-Met/HGF receptor in combination with
HGF/NK2. Therefore, the N-terminal hairpin structure and subsequent two kringle domains (K1 and K2) are a specific motif for the high affinity
binding of HGF and HGF/NK4 to c-Met/HGF receptor, while K3 and/or K4 in
HGF/NK4 are essential for exposing the specific binding site of HGF/
on the c-Met/HGF receptor occupied by HGF/NK4. In this context, it is
noteworthy that the
-chain alone of HGF-like protein/macrophage-stimulating protein, a family molecule of HGF, directly binds to its receptor, Ron (40). It is interesting to assume
that HGF/
also has a putative binding motif to c-Met/HGF receptor,
but in the case of HGF/
, the binding of HGF/
depends on the
preoccupation of c-Met/HGF receptor with HGF/NK4.
HGF/NK2 elicits motogenic activity, but competitively antagonizes the
mitogenic activity of HGF (23, 25, 26). Together with our earlier
finding that HGF with K3 or K4 deleted still sustains significant
mitogenic activity (30, 31), the importance of the
-chain for the
optimal activation of c-Met/HGF receptor has been equivocally
considered. Of particular importance in our present results is that,
although HGF/
itself does not play a role in a specific recognition
processes between HGF and the c-Met/HGF receptor, HGF/
is an
indispensable domain for the optimum activation and subsequent
activation of intracellular signal transduction pathways that lead to
mitogenic, motogenic, and morphogenic responses. How does HGF/
induce tyrosine phosphorylation of the c-Met/HGF receptor and activate
mitogenic, motogenic, and morphogenic responses? Schwall et
al. (39) reported that heparin dimerizes HGF/NK1 and confers
mitogenic activity, suggesting that heparin-induced dimerization of
HGF/NK1 in turn may facilitate dimerization and activation of c-Met/HGF
receptor. One possible role of HGF/
is likely to be that HGF/
may
facilitate dimerization of the receptor, through inducing dimerization
and/or stabilization of the ligand. Donate et al. (41)
implicated the possibility of HGF to form a noncovalently linked
homodimer, through putative interactions between K2 and K3 and/or
HGF/
of each HGF molecule. However, we could not detect
HGF/
-dependent dimerization or oligomerization of
c-Met/HGF receptor in our affinity cross-linking experiment (Fig. 7).
On the other hand, given that the c-Met/HGF receptor exists in a
preassociated form, one possible explanation for the role of HGF/
is
that the binding of HGF/
to c-Met/HGF receptor occupied with HGF/NK4
can induce the allosteric conformational change required for activation
of tyrosine kinase. Which mechanism is involved in activation of the
c-Met/HGF receptor should be further analyzed; however, the separation
of the two distinct biochemical events, i.e. receptor
binding and receptor activation, through utilizing HGF/NK4 and HGF/
would provide insights into the initial mechanism involved in
activation of c-Met/HGF receptor.
In conclusion, we here show that, although HGF/
alone cannot bind to
c-Met/HGF receptor, HGF/
can bind to the c-Met/HGF receptor occupied
with HGF/NK4 and that the binding of HGF/
induces tyrosine
phosphorylation of the receptor and subsequent mitogenic, motogenic,
and morphogenic responses in cells. Clearly, the
- and
-chains of
HGF have distinct functions. The N-terminal hairpin- and
kringle-containing
-chain is a motif which specifies high affinity
binding to the c-Met/HGF receptor, while the
-chain seems to play a
role in optimal activation of the c-Met/HGF receptor, which enables
mitogenic, motogenic, and morphogenic actions of HGF.
| |
ACKNOWLEDGEMENTS |
|---|
We are grateful to M. Ohara for translation assistance and to M. Eguchi and K. Bessho for technical assistance.
| |
FOOTNOTES |
|---|
* This study was supported by a Research Grant for Science and Cancer from the Ministry of Education, Science, Sports, and Culture of Japan, and grants from Sagawa Cancer Research Foundation, the Ryoichi Naito Foundation for Medical Research, Kudo Foundation, and Tanabe Medical Science Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.: 81-6-879-3783;
Fax: 81-6-879-3789; E-mail: nakamura{at}onbich.med.osaka-u.ac.jp.
The abbreviations used are:
HGF, hepatocyte
growth factor; TGF-
, transforming growth factor-
; PAGE, polyacrylamide gel electrophoresis; HPLC, high performance liquid
chromatography; MDCK, Madin-Darby canine kidney cells.
2 K. Matsumoto, H. Kataoka, K. Date, and T. Nakamura, unpublished observation.
| |
REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
W. W. Raymond, A. C. Cruz, and G. H. Caughey Mast Cell and Neutrophil Peptidases Attack an Inactivation Segment in Hepatocyte Growth Factor to Generate NK4-like Antagonists J. Biol. Chem., January 20, 2006; 281(3): 1489 - 1494. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kirchhofer, X. Yao, M. Peek, C. Eigenbrot, M. T. Lipari, K. L. Billeci, H. R. Maun, P. Moran, L. Santell, C. Wiesmann, et al. Structural and Functional Basis of the Serine Protease-like Hepatocyte Growth Factor {beta}-Chain in Met Binding and Signaling J. Biol. Chem., September 17, 2004; 279(38): 39915 - 39924. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Martin, C. Parr, G. Davies, G. Watkins, J. Lane, K. Matsumoto, T. Nakamura, R. E. Mansel, and W. G. Jiang Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist Carcinogenesis, August 1, 2003; 24(8): 1317 - 1323. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Saimura, E. Nagai, K. Mizumoto, N. Maehara, Y. A. Minamishima, M. Katano, K. Matsumoto, T. Nakamura, and M. Tanaka Tumor Suppression through Angiogenesis Inhibition by SUIT-2 Pancreatic Cancer Cells Genetically Engineered to Secrete NK4 Clin. Cancer Res., October 1, 2002; 8(10): 3243 - 3249. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. LIU, K. L. SCHAPHORST, A. D. VERIN, K. JACOBS, A. BIRUKOVA, R. M. DAY, N. BOGATCHEVA, D. P. BOTTARO, and J. G. N. GARCIA Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3{beta} FASEB J, July 1, 2002; 16(9): 950 - 962. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. G. Jiang, D. Grimshaw, J. Lane, T. A. Martin, R. Abounder, J. Laterra, and R. E. Mansel A Hammerhead Ribozyme Suppresses Expression of Hepatocyte Growth Factor/Scatter Factor Receptor c-MET and Reduces Migration and Invasiveness of Breast Cancer Cells Clin. Cancer Res., August 1, 2001; 7(8): 2555 - 2562. [Abstract] [Full Text] [PDF] |
||||
![]() |
|